Nothing Special   »   [go: up one dir, main page]

US20040224892A1 - Oligosaccharides in cosmetic or dermatological compositions for stimulating adhesion of keratinocytes to major proteins of the dermoepidermal junction and restoration of epidermal cohesion - Google Patents

Oligosaccharides in cosmetic or dermatological compositions for stimulating adhesion of keratinocytes to major proteins of the dermoepidermal junction and restoration of epidermal cohesion Download PDF

Info

Publication number
US20040224892A1
US20040224892A1 US10/839,420 US83942004A US2004224892A1 US 20040224892 A1 US20040224892 A1 US 20040224892A1 US 83942004 A US83942004 A US 83942004A US 2004224892 A1 US2004224892 A1 US 2004224892A1
Authority
US
United States
Prior art keywords
composition according
epidermis
oligogalacturonides
hydrolysis
laminin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/839,420
Inventor
Christian Lubrano
Laurence Flavet
Gaelle Saintigny
Jean-Renaud Robin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires de Biologie Vegetale Yves Rocher SA
Original Assignee
Laboratoires de Biologie Vegetale Yves Rocher SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires de Biologie Vegetale Yves Rocher SA filed Critical Laboratoires de Biologie Vegetale Yves Rocher SA
Assigned to LABORATOIRES DE BIOLOGIE VEGETALE YVES ROCHER reassignment LABORATOIRES DE BIOLOGIE VEGETALE YVES ROCHER ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FLAVET, LAURENCE, LUBRANO, CHRISTIAN, ROBIN, JEAN-RENAUD, SAINTIGNY GAELLE
Publication of US20040224892A1 publication Critical patent/US20040224892A1/en
Priority to US11/894,945 priority Critical patent/US20070293433A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders

Definitions

  • This invention relates to new cosmetic compositions for skin care with an antiaging intent. More particularly, the invention pertains to the cosmetic use of a mixture of oligosaccharides of the type obtained by enzymatic hydrolysis of a pectin.
  • the oligosaccharides stimulate adhesion of keratinocytes to proteins of the dermoepidermal junction (laminin V and collagen IV).
  • the compositions of the invention can resolve disturbances in communication between the dermis and the epidermis and the decrease in the interkeratinocyte cohesion within the epidermis that appear during cutaneous aging and thereby restore epidermal cohesion.
  • the basal membrane of the skin or dermoepidermal junction corresponds to the zone comprised anatomically between the basal cells of the epidermis and the more superficial layers of the dermis. This is a zone of adherence between the epidermis and the dermis, providing for the control of the filtration of small molecules and the maintenance of the adjacent cells (Damour O., M. C. Martini and P. Rousselle, October 1998, Cutaneous Aging, pub. Flash Media).
  • the DEJ comprises specific attachment complexes, the hemidesmosomes, whose function is to provide a bond between basal keratinocytes of the epidermis and the subjacent basal membrane (Kelly, 1966, J. Cell. Biol., 28: 51-73).
  • the DEJ plays a very important role both on the mechanical level, since it enables solid anchoring of the epidermis, as well as on the biological level, since it intervenes in cell signalization via the integrin family of receptors.
  • Integrins are transmembranal glycoproteins located on the basal part of the keratinocyte in contact with the DEJ. They have an extracellular part enabling recognition with the characteristic proteins of the DEJ.
  • laminin V which is a constitutive protein of the hemidesmosomes, and collagen IV.
  • These proteins via the membrane receptors (the ⁇ 6 ⁇ 4 ⁇ 3 ⁇ 1 integrins for laminin V and the ⁇ 2 ⁇ 1 integrins for collagen IV), enable: adhesion of the basal keratinocytes to the support according to a clearly defined orientation, and transmission of signals from the dermis to the epidermis as proliferation signals, differentiation of the keratinocytes.
  • These integrins are, thus, veritable zones of dialogue between the interior and the exterior of the cell and beyond that of the basal layer, they contribute, by promoting cellular adhesion to better communication between the principal compartments of the skin, the dermis and the epidermis.
  • This invention relates to a dermatological composition including a therapeutically effective amount of an agent stimulating adherence of basal keratinocytes to laminin V and/or collagen IV that reduces communication disturbances between a subject's dermis and epidermis and reduces diminishment in interkeratinocyte cohesion within the epidermis.
  • This invention also relates to a method of preparing oligogalacturonides including hydrolysis of a pectin solution at a concentration of about 0.1 to about 10% at an acidic pH, by addition to the pectin solution of an enzyme solution of about 10 to about 1000 polygalacturonase units to obtain in a final solution of about 1 to about 10 pectinase units; stopping the hydrolysis; separation of resulting high-molecular-weight polymers from the final solution; and recovery of the oligogalacturonides.
  • This invention further relates to a method of preventing aging of skin including applying a therapeutically effective amount of the composition stimulating adherence of basal keratinocytes to laminin V and/or collagen IV that resolves communication disturbances between a subject's dermis and epidermis and diminishment in interkeratinocyte cohesion within the epidermis to the skin.
  • This invention still further relates to a method of reducing decreases in interkeratinocyte cohesion is skin including applying a therapeutically effective amount of the composition stimulating adherence of basal keratinocytes to laminin V and/or collagen IV that resolves communication disturbances between a subject's dermis and epidermis and diminishment in interkeratihocyte cohesion within the epidermis to the skin.
  • FIGS. 1A and 1B are photographs showing the number of cells adhered to laminin V.
  • FIG. 1A is a control and FIG. 1B is in accordance with aspects of the invention.
  • FIGS. 2A and 2B are photographs showing the number of cells adhered to collagen IV.
  • FIG. 2A is a control and FIG. 2B is in accordance with aspects of the invention.
  • This invention relates to a means of cosmetic or dermatological compositions for skin care and, more particularly, for combating aging of the skin, comprising oligogalacturonides as an active ingredient.
  • Application of the composition according to aspects of the invention promotes adhesion of cells to two proteins of the DEJ by an enhanced availability of the ⁇ 6 ⁇ 4 receptors for laminin V and the ⁇ 2 ⁇ 1 receptors for collagen IV.
  • the composition according to aspects of the invention induces activation of these receptors by means of a change of conformation.
  • the oligogalacturonides of the compositions according to the invention preferably have a degree of polymerization between about 1 and about 5.
  • the oligogalacturonides of the compositions according to the invention are at least partially methylated or esterified.
  • the cosmetic compositions of the invention comprise, in dry equivalent in relation to the total weight of the composition, from about 0.01 to about 5%, preferably about 0.5%, of oligogalacturonides.
  • the cosmetic compositions of the invention can also comprise other active substances, more specifically plant extracts.
  • extracts include: a yam extract (Dioscorea) with a content of diosgenin or pure diosgenin. This can be an extract containing about 15% of diosgenin or a solution of pure diosgenin; and pure or diluted beta carotene in the form of a suspension in oil, notably, a about 30% dilution.
  • compositions according to the invention can also comprise one or more formulation agents or additives of common and conventional use in cosmetic and dermatological compositions such as, as nonlimitative examples, softeners, colorants, film-forming agents, surface-active agents, perfumes, preservatives, emulsifiers, oils, glycols, sebum-absorbing agents, vitamins and the like.
  • formulation agents or additives of common and conventional use in cosmetic and dermatological compositions such as, as nonlimitative examples, softeners, colorants, film-forming agents, surface-active agents, perfumes, preservatives, emulsifiers, oils, glycols, sebum-absorbing agents, vitamins and the like.
  • compositions according to the invention can be made available in any form known in art of cosmetology and dermatology without any pharmaceutical restriction other than application to the skin of the face or the body.
  • the compositions according to the invention are advantageously presented in the form of a gel, a cream, an emulsion, a milk, a spray and the like.
  • the oligogalacturonides of the compositions according to the invention are advantageously obtained by enzymatic hydrolysis of a pectin.
  • Pectin is constituted of a principal chain called “pectic acid” comprising a chain of galacturonic acid type sugars.
  • the constitutive sugars can be methylated or esterified, and the proportion of transformed sugars is characteristic of a plant species.
  • the principal chain is sometimes interrupted by the insertion of a side chain of neutral sugars such as rhamnose or glucose.
  • oligogalacturonides previously referred to as oligosaccharines, have been described as veritable plant hormones (Darvill et al., Glycobiology, vol. 2, no. 3 , pp 181-198, 1992). They can be prepared by hydrolysis of pectin; the size or degree of polymerization of the oligogalacturonides is a function of the conditions of the hydrolysis reaction.
  • oligogalacturonides providing an industrial product that is effective as a cosmetic agent.
  • Numerous pectins are available commercially in large quantity and variable quality. These are often standardized pectins that frequently contain added sugars to enable homogenization of the viscosities among the batches. In fact, the first use of these pectins is linked to their gelling properties and as viscosity agents.
  • the oligogalacturonides employed in the compositions of the invention are preferably prepared by hydrolysis of pectin having a low degree of methylation and esterification to be as close as possible to polygalacturonic acid.
  • pectin type HB AU The pectins of the type HERBSTREITH and FOX Classic AU 910 obtained from apples (pectin type HB AU) are an example of such a pectin.
  • the enzymes used for the hydrolysis of pectin are of the industrial type frequently used in the fruit juice processing industry. These are cocktails of enzymes conceived to cut the membranal pectins and thereby enable better extraction of the fruit juices by making the structures fragile prior to pressing. They also make possible clarification of the juices in which turbidity—often linked to pectins—is not desirable.
  • the enzyme marketed by the company LYVEN as Clarification granulated is an example of such an enzyme.
  • the enzyme cocktail comprises pectinases having principally polygalacturonase, methyl esterase and polygalacturonase lyase activities.
  • a preferred method for preparing oligogalacturonides according to the invention comprises the following steps:
  • the hydrolysis is advantageously performed at about 50° C. for about 2 hours then stopped by heating at about 70° C. for about 1 hour or at about 100° C. for about 5 minutes.
  • the high-molecular-weight polymers are preferably precipitated by addition of HCl 1N then eliminated by centrifugation, e.g., at about 5000 g for about 30 minutes or by filtration.
  • the pH of the supernatant is then readjusted to a value between about 6 and about 8, e.g., on the order of about 6.9.
  • the invention also relates the use in cosmetics or for the preparation of a pharmaceutical composition, notably a dermatological composition, of oligogalacturonides as defined above as an agent stimulating adherence of the basal keratinocytes to the two major proteins of the DEJ, which are laminin V and collagen IV, and resolve the disturbances of communication between the dermis and the epidermis, and the diminishment in the interkeratinocyte cohesion within the epidermis, which appear during cutaneous aging.
  • a pharmaceutical composition notably a dermatological composition, of oligogalacturonides as defined above as an agent stimulating adherence of the basal keratinocytes to the two major proteins of the DEJ, which are laminin V and collagen IV, and resolve the disturbances of communication between the dermis and the epidermis, and the diminishment in the interkeratinocyte cohesion within the epidermis, which appear during cutaneous aging.
  • the invention also pertains to a cosmetic method for resolving the disturbances in communication between the dermis and the epidermis, and the diminishment in interkeratinocyte cohesion within the epidermis, which appear during cutaneous aging and thereby to restore the epidermis cohesion comprising applying to the skin a therapeutically effective amount of oligogalacturonides or of a composition containing them as defined above.
  • Pectin put in solution at from 0.1 to 10% (1% of pectin HB AU910).
  • the pH is adjusted to 4.5, preferably with an acetic acid solution.
  • Enzyme A solution is prepared corresponding to 10 to 1000, preferably 100, polygalacturonase units. The enzymatic solution is added to the pectin solution to obtain at the end a solution of 1 to 10, preferably 4, pectinase units. Hydrolysis is performed at 50° C. for 2 hours then stopped by heating at 70° C. for 1 hour or at 100° C. for 5 minutes. After cooling, the high-molecular-weight polymers are precipitated by addition of HCl 1N then eliminated by centrifugation, e.g., at 5000 g for 30 minutes or by filtration. The pH of the supernatant is readjusted at the end to a value comprised between 6 and 8, e.g., on the order of 6.9.
  • the oligogalacturonides formed are advantageously atomized or lyophilized at the end to enable better preservation and easier handling.
  • Oven temperature 130° C.
  • Nitrogen flow rate 4.0 SLPM (standard liter per minute): standard conditions for H 2 O as solvent.
  • the culture medium employed was the defined medium for keratinocyte culture 154 (+additive HKGS) manufactured by Cascade Inc. (USA) and marketed by Tebu (France) containing 0.2 mM of CaCl 2 , pH 7.2 to 7.4.
  • the keratinocytes were obtained according to the technique described by Boyce and Ham (Boyce S T, Ham R G, J. Invest. Dermatol., 1983, 81, 33s-40s). Pieces of human skin obtain from human prepuces (circumcision) were treated in a manner to isolate their basal human keratinocytes. 3 ⁇ 10 4 live cells were then seeded per cm 2 on 25-cm 2 tissue culture dishes (Coming, Polylabo, France).
  • the keratinocytes were cultured at 37° C. in an incubator with CO 2 (5% of CO 2 , 95% of air and 98% humidity). The medium was changed every two days. Subculture took place when the cells reached subconfluence. The cell layer was then rinsed with PBS, then the cells were trypsinated using the conventional trypsination technique (Trypsin-EDTA (0.05-0.02%) at 37° C.). The cells were then seeded in 75-cm 2 culture dishes.
  • CO 2 5% of CO 2 , 95% of air and 98% humidity
  • Freezing the cells 3 to 5 million per ampoule, was performed in the culture medium employed, in the presence of 10% dimethyl sulfoxide (DMSO) and 20% of calf serum in a volume of 1 ml.
  • DMSO dimethyl sulfoxide
  • a dose-response for each of the adhesion substrates was determined to establish the ideal concentration of the adherence proteins that will subsequently be used.
  • Collagen IV (Becton Dickinson, France), fibronectin (Becton Dickinson, France) and laminin 5 , purified in the laboratory (Pousselle P. et al., J. Cell. Biol., 1991, 114(3); 567-576) were used in our experiments.
  • a range of seven decreasing concentrations was created by successive dilution in distilled water, from a starting solution of 10 ⁇ g/ml. These solutions were immediately distributed on 96-well culture plates (Costar, Dutscher, Brumath, France) at the rate of 100 ⁇ g per well. The plates were then placed at +4° C. for 16 to 18 hours. The solutions were then removed by turning over the plates and each well was saturated by an aqueous solution of SAB 1% (3 supplementary wells without substrate were subjected to the same treatment and functioned as blanks).
  • the cells were trypsinated as described above, then suspended in the medium 154 without additives (3 ⁇ 10 5 cells/ml) then seeded in passage 2 in multiwell plates of 100 ⁇ l/well.
  • the multiwell plates were placed in an incubator at 37° C. for a duration of 45 minutes in the presence of or absence of the oligogalacturonide mixture at different noncytotoxic concentrations in the culture medium.
  • a positive control was implemented in parallel (manganese chloride (0.5 mM)) to validate the experiment. After incubation, the cells were observed with a phase-contrast microscope to verify that the test had taken place correctly.
  • Manganese chloride (0.5 mM) was used as a positive control for the adhesion of the cells to the substrate.
  • the adherence result obtained with the cells without active ingredient and without positive control was set arbitrarily at 100%.
  • the active ingredient identified here constitutes the reference solution of oligosaccharides type oligo G04 (not lyophilized).
  • Manganese chloride (0.5 mM) was used as positive control for the adhesion of the cells to the substrate.
  • the adherence results obtained with the cells without active ingredient and without positive control was set arbitrarily at 100%.
  • FIGS. 1A and 1B show that, in the presence of the active ingredient used at 0.01% (FIG. 1B), the number of cells having adhered to laminin V was greater than in the control (FIG. 1A). These cells are more spread apart and the representative actin network of the cellular cytoskeleton is much better organized. These morphological changes due to the presence of the active ingredient (compared to the control) indicate that this ingredient truly promotes the recruitment and activation of the integrin ⁇ 6 ⁇ 4.
  • the oligogalacturonides can be incorporated at the rate of about 0.1 to about 5%, preferably at the rate of about 0.5%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)

Abstract

A dermatological composition including a therapeutically effective amount of an agent stimulating adherence of basal keratinocytes to laminin V and/or collagen IV that resolves communication disturbances between a subject's dermis and epidermis and diminishment in interkeratinocyte cohesion within the epidermis.

Description

    RELATED APPLICATION
  • This is a continuation of International Application No. PCT/FR02/03844, with an international filing date of Nov. 8, 2002 (WO 03/039509, published May 15, 2003), which is based on French Patent Application No. 01/14463, filed Nov. 8, 2001. [0001]
  • FIELD OF THE INVENTION
  • This invention relates to new cosmetic compositions for skin care with an antiaging intent. More particularly, the invention pertains to the cosmetic use of a mixture of oligosaccharides of the type obtained by enzymatic hydrolysis of a pectin. The oligosaccharides stimulate adhesion of keratinocytes to proteins of the dermoepidermal junction (laminin V and collagen IV). The compositions of the invention can resolve disturbances in communication between the dermis and the epidermis and the decrease in the interkeratinocyte cohesion within the epidermis that appear during cutaneous aging and thereby restore epidermal cohesion. [0002]
  • BACKGROUND
  • The basal membrane of the skin or dermoepidermal junction (DEJ) corresponds to the zone comprised anatomically between the basal cells of the epidermis and the more superficial layers of the dermis. This is a zone of adherence between the epidermis and the dermis, providing for the control of the filtration of small molecules and the maintenance of the adjacent cells (Damour O., M. C. Martini and P. Rousselle, October 1998, Cutaneous Aging, pub. Flash Media). [0003]
  • The DEJ comprises specific attachment complexes, the hemidesmosomes, whose function is to provide a bond between basal keratinocytes of the epidermis and the subjacent basal membrane (Kelly, 1966, J. Cell. Biol., 28: 51-73). The DEJ plays a very important role both on the mechanical level, since it enables solid anchoring of the epidermis, as well as on the biological level, since it intervenes in cell signalization via the integrin family of receptors. [0004]
  • Integrins are transmembranal glycoproteins located on the basal part of the keratinocyte in contact with the DEJ. They have an extracellular part enabling recognition with the characteristic proteins of the DEJ. Among the components of the DEJ, we can cite two proteins which play a fundamental role within the DEJ: laminin V, which is a constitutive protein of the hemidesmosomes, and collagen IV. [0005]
  • These proteins, via the membrane receptors (the α6β4 α3β1 integrins for laminin V and the α2β1 integrins for collagen IV), enable: adhesion of the basal keratinocytes to the support according to a clearly defined orientation, and transmission of signals from the dermis to the epidermis as proliferation signals, differentiation of the keratinocytes. These integrins are, thus, veritable zones of dialogue between the interior and the exterior of the cell and beyond that of the basal layer, they contribute, by promoting cellular adhesion to better communication between the principal compartments of the skin, the dermis and the epidermis. [0006]
  • More recently, it has been shown that adhesion of the basal keratinocytes to the major proteins of the DEJ, such as laminin V, collagen IV and fibronectin, appears to regulate the expression of the junctions (junction gap) between the keratinocytes of the epidermis (Lampe et al., J. Cell. Biol., 1998, 1735-1747). Thus, an increase in the interactions between especially laminin V and the basal keratinocytes via integrins such as α6β4 α3β1 generates the emission of signals within the epidermis to promote formation of intercellular junctions and enable better communication among keratinocytes of the epidermis. [0007]
  • During cutaneous aging, there is seen a flatting and a thinning of the DEJ. The adherence properties of the epidermis are decreased because of a diminishment in the expression of the integrins specifically involved in the adhesion of the basal keratinocytes (Levarlet et al., 1998, J. Invest. Dermatol., 3: 172-9). All of these changes lead to a diminishment in communication between the various compartments, probably contributing to dermoepidermal disorganization. [0008]
  • Even though not all of the mechanisms have been clarified, everything leads one to believe that an augmentation of the adherence of the cells, especially to the DEJ, enables reestablishment of better dermoepidermal communication as well as better epidermal cohesion leading to the restoration of a better coordination of the functions of the skin. In fact, disturbances in the dermoepidermal communication, on the one hand, and at the level of the cohesion among the keratinocytes of the epidermis, on the other hand, could lead to disturbances in coordination of the cell functions such as proliferation and/or epidermal differentiation. [0009]
  • It would, therefore, be advantageious to provide means enabling augmentation specifically of the adherence of basal keratinocytes to the two major proteins of the DEJ, which are laminin V and collagen IV, to resolve disturbances in communication between the dermis and the epidermis, and diminishment in interkeratinocyte cohesion that appear during cutaneous aging. [0010]
  • SUMMARY OF THE INVENTION
  • This invention relates to a dermatological composition including a therapeutically effective amount of an agent stimulating adherence of basal keratinocytes to laminin V and/or collagen IV that reduces communication disturbances between a subject's dermis and epidermis and reduces diminishment in interkeratinocyte cohesion within the epidermis. [0011]
  • This invention also relates to a method of preparing oligogalacturonides including hydrolysis of a pectin solution at a concentration of about 0.1 to about 10% at an acidic pH, by addition to the pectin solution of an enzyme solution of about 10 to about 1000 polygalacturonase units to obtain in a final solution of about 1 to about 10 pectinase units; stopping the hydrolysis; separation of resulting high-molecular-weight polymers from the final solution; and recovery of the oligogalacturonides. [0012]
  • This invention further relates to a method of preventing aging of skin including applying a therapeutically effective amount of the composition stimulating adherence of basal keratinocytes to laminin V and/or collagen IV that resolves communication disturbances between a subject's dermis and epidermis and diminishment in interkeratinocyte cohesion within the epidermis to the skin. [0013]
  • This invention still further relates to a method of reducing decreases in interkeratinocyte cohesion is skin including applying a therapeutically effective amount of the composition stimulating adherence of basal keratinocytes to laminin V and/or collagen IV that resolves communication disturbances between a subject's dermis and epidermis and diminishment in interkeratihocyte cohesion within the epidermis to the skin.[0014]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIGS. 1A and 1B are photographs showing the number of cells adhered to laminin V. FIG. 1A is a control and FIG. 1B is in accordance with aspects of the invention. [0015]
  • FIGS. 2A and 2B are photographs showing the number of cells adhered to collagen IV. FIG. 2A is a control and FIG. 2B is in accordance with aspects of the invention. [0016]
  • DETAILED DESCRIPTION
  • This invention relates to a means of cosmetic or dermatological compositions for skin care and, more particularly, for combating aging of the skin, comprising oligogalacturonides as an active ingredient. Application of the composition according to aspects of the invention promotes adhesion of cells to two proteins of the DEJ by an enhanced availability of the α6β4 receptors for laminin V and the α2β1 receptors for collagen IV. The composition according to aspects of the invention induces activation of these receptors by means of a change of conformation. [0017]
  • The oligogalacturonides of the compositions according to the invention preferably have a degree of polymerization between about 1 and about 5. The oligogalacturonides of the compositions according to the invention are at least partially methylated or esterified. The cosmetic compositions of the invention comprise, in dry equivalent in relation to the total weight of the composition, from about 0.01 to about 5%, preferably about 0.5%, of oligogalacturonides. [0018]
  • In addition to the oligogalacturonides, the cosmetic compositions of the invention can also comprise other active substances, more specifically plant extracts. Examples of such extracts include: a yam extract (Dioscorea) with a content of diosgenin or pure diosgenin. This can be an extract containing about 15% of diosgenin or a solution of pure diosgenin; and pure or diluted beta carotene in the form of a suspension in oil, notably, a about 30% dilution. [0019]
  • The compositions according to the invention can also comprise one or more formulation agents or additives of common and conventional use in cosmetic and dermatological compositions such as, as nonlimitative examples, softeners, colorants, film-forming agents, surface-active agents, perfumes, preservatives, emulsifiers, oils, glycols, sebum-absorbing agents, vitamins and the like. Those skilled in the art know which formulation agents to add to the compositions of the invention and what amounts in relation to the desired properties. [0020]
  • The compositions according to the invention can be made available in any form known in art of cosmetology and dermatology without any pharmaceutical restriction other than application to the skin of the face or the body. The compositions according to the invention are advantageously presented in the form of a gel, a cream, an emulsion, a milk, a spray and the like. [0021]
  • The oligogalacturonides of the compositions according to the invention are advantageously obtained by enzymatic hydrolysis of a pectin. Pectin is constituted of a principal chain called “pectic acid” comprising a chain of galacturonic acid type sugars. The constitutive sugars can be methylated or esterified, and the proportion of transformed sugars is characteristic of a plant species. The principal chain is sometimes interrupted by the insertion of a side chain of neutral sugars such as rhamnose or glucose. [0022]
  • The oligogalacturonides, previously referred to as oligosaccharines, have been described as veritable plant hormones (Darvill et al., Glycobiology, vol. 2, no. [0023] 3, pp 181-198, 1992). They can be prepared by hydrolysis of pectin; the size or degree of polymerization of the oligogalacturonides is a function of the conditions of the hydrolysis reaction.
  • We have now developed a method for preparing oligogalacturonides providing an industrial product that is effective as a cosmetic agent. Numerous pectins are available commercially in large quantity and variable quality. These are often standardized pectins that frequently contain added sugars to enable homogenization of the viscosities among the batches. In fact, the first use of these pectins is linked to their gelling properties and as viscosity agents. The oligogalacturonides employed in the compositions of the invention are preferably prepared by hydrolysis of pectin having a low degree of methylation and esterification to be as close as possible to polygalacturonic acid. [0024]
  • The pectins of the type HERBSTREITH and FOX Classic AU 910 obtained from apples (pectin type HB AU) are an example of such a pectin. The enzymes used for the hydrolysis of pectin are of the industrial type frequently used in the fruit juice processing industry. These are cocktails of enzymes conceived to cut the membranal pectins and thereby enable better extraction of the fruit juices by making the structures fragile prior to pressing. They also make possible clarification of the juices in which turbidity—often linked to pectins—is not desirable. The enzyme marketed by the company LYVEN as Clarification granulated is an example of such an enzyme. The enzyme cocktail comprises pectinases having principally polygalacturonase, methyl esterase and polygalacturonase lyase activities. [0025]
  • A preferred method for preparing oligogalacturonides according to the invention comprises the following steps: [0026]
  • hydrolysis of a pectin solution at a concentration of about 0.1 to about 10%, preferably at about 1%, at a pH of about 4.5, by addition to the pectin solution of an enzyme solution comprising from about 10 to about 1000, preferably about 100, polygalacturonase units to obtain in the final solution from about 1 to about 10, preferably about 4, pectinase units; [0027]
  • stopping the hydrolysis; and [0028]
  • separation of the high-molecular-weight polymers and recovery of the oligogalacturonides. [0029]
  • The hydrolysis is advantageously performed at about 50° C. for about 2 hours then stopped by heating at about 70° C. for about 1 hour or at about 100° C. for about 5 minutes. After cooling, the high-molecular-weight polymers are preferably precipitated by addition of HCl 1N then eliminated by centrifugation, e.g., at about 5000 g for about 30 minutes or by filtration. The pH of the supernatant is then readjusted to a value between about 6 and about 8, e.g., on the order of about 6.9. [0030]
  • The invention also relates the use in cosmetics or for the preparation of a pharmaceutical composition, notably a dermatological composition, of oligogalacturonides as defined above as an agent stimulating adherence of the basal keratinocytes to the two major proteins of the DEJ, which are laminin V and collagen IV, and resolve the disturbances of communication between the dermis and the epidermis, and the diminishment in the interkeratinocyte cohesion within the epidermis, which appear during cutaneous aging. [0031]
  • The invention also pertains to a cosmetic method for resolving the disturbances in communication between the dermis and the epidermis, and the diminishment in interkeratinocyte cohesion within the epidermis, which appear during cutaneous aging and thereby to restore the epidermis cohesion comprising applying to the skin a therapeutically effective amount of oligogalacturonides or of a composition containing them as defined above. [0032]
  • Other advantages and characteristics of the invention will emerge from the examples below concerning the preparation of oligogalacturonides and their use as cosmetic agent. [0033]
  • EXAMPLES
  • I. Preparation of the oligogalacturonides [0034]
  • 1) Operating procedure [0035]
  • Pectin: put in solution at from 0.1 to 10% (1% of pectin HB AU910). [0036]
  • The pH is adjusted to 4.5, preferably with an acetic acid solution. [0037]
  • Enzyme: A solution is prepared corresponding to 10 to 1000, preferably 100, polygalacturonase units. The enzymatic solution is added to the pectin solution to obtain at the end a solution of 1 to 10, preferably 4, pectinase units. Hydrolysis is performed at 50° C. for 2 hours then stopped by heating at 70° C. for 1 hour or at 100° C. for 5 minutes. After cooling, the high-molecular-weight polymers are precipitated by addition of HCl 1N then eliminated by centrifugation, e.g., at 5000 g for 30 minutes or by filtration. The pH of the supernatant is readjusted at the end to a value comprised between 6 and 8, e.g., on the order of 6.9. [0038]
  • The oligogalacturonides formed are advantageously atomized or lyophilized at the end to enable better preservation and easier handling. [0039]
  • 2) HPLC anaylsis of the oligogalacturonides formed [0040]
  • An analysis technique producing a chromatographic profile of the oligogalacturonides formed was developed. [0041]
  • Column: TSK gel DEAE 5-PW (TOSOHAAS) [0042]
  • Eluent: CH[0043] 3COONH4 1M/H2O in elution gradient
  • Mobile phase flow rate: 1 ml/min [0044]
  • Light diffusion evaporative detector (DEDL; ALTECH). [0045]
  • Oven temperature: 130° C. [0046]
  • Nitrogen flow rate: 4.0 SLPM (standard liter per minute): standard conditions for H[0047] 2O as solvent.
  • The selection of the gradient is presented in Table 1 below: [0048]
    TABLE 1
    Time in minutes % A (CH3COONH4 1M) % B (H2O)
    0 10 90
    1 30 70
    3 30 70
    30 50 50
    45 50 50
  • We observe a distribution of the oligomers by size (dp: degree of polymerization) from 1 to 5. [0049]
  • The absence of a standard does not allow quantitative determination of the oligomers of dp 4 and 5, but quantitative determination of the shorter oligomers is possible. [0050]
  • If we proceed according to the conditions described for hydrolysis of a pectin solution of conentration 10 g/l, the total concentration in mono-, di- and trigalacturonic acid is approximately 4.5 g/l at the end, thus approximately 45% by weight of the pectin put in solution. [0051]
  • II. Effects of the Oligogalacturonides on the Adhesion of Human Keratinocytes to Laminin V and to Collagen IV [0052]
  • 1) Material and Methods [0053]
  • a) Culture of the Keratinocytes in Defined Medium [0054]
  • The culture medium employed was the defined medium for keratinocyte culture [0055] 154 (+additive HKGS) manufactured by Cascade Inc. (USA) and marketed by Tebu (France) containing 0.2 mM of CaCl2, pH 7.2 to 7.4.
  • The keratinocytes were obtained according to the technique described by Boyce and Ham (Boyce S T, Ham R G, J. Invest. Dermatol., 1983, 81, 33s-40s). Pieces of human skin obtain from human prepuces (circumcision) were treated in a manner to isolate their basal human keratinocytes. 3·10[0056] 4 live cells were then seeded per cm2 on 25-cm2 tissue culture dishes (Coming, Polylabo, France).
  • The keratinocytes were cultured at 37° C. in an incubator with CO[0057] 2 (5% of CO2, 95% of air and 98% humidity). The medium was changed every two days. Subculture took place when the cells reached subconfluence. The cell layer was then rinsed with PBS, then the cells were trypsinated using the conventional trypsination technique (Trypsin-EDTA (0.05-0.02%) at 37° C.). The cells were then seeded in 75-cm2 culture dishes.
  • Freezing the cells, 3 to 5 million per ampoule, was performed in the culture medium employed, in the presence of 10% dimethyl sulfoxide (DMSO) and 20% of calf serum in a volume of 1 ml. [0058]
  • b) Quantitative Analysis of Cellular Adherence by a Calorimetric Test [0059]
  • Preparation of the Adherence Substrates [0060]
  • A dose-response for each of the adhesion substrates was determined to establish the ideal concentration of the adherence proteins that will subsequently be used. [0061]
  • Collagen IV (Becton Dickinson, France), fibronectin (Becton Dickinson, France) and laminin [0062] 5, purified in the laboratory (Pousselle P. et al., J. Cell. Biol., 1991, 114(3); 567-576) were used in our experiments. A range of seven decreasing concentrations was created by successive dilution in distilled water, from a starting solution of 10 μg/ml. These solutions were immediately distributed on 96-well culture plates (Costar, Dutscher, Brumath, France) at the rate of 100 μg per well. The plates were then placed at +4° C. for 16 to 18 hours. The solutions were then removed by turning over the plates and each well was saturated by an aqueous solution of SAB 1% (3 supplementary wells without substrate were subjected to the same treatment and functioned as blanks).
  • Test of Cellular Adherence [0063]
  • The cells were trypsinated as described above, then suspended in the medium [0064] 154 without additives (3×105 cells/ml) then seeded in passage 2 in multiwell plates of 100 μl/well.
  • Evaluation of the Cellular Adherence Test [0065]
  • After seeding of the cells, the multiwell plates were placed in an incubator at 37° C. for a duration of 45 minutes in the presence of or absence of the oligogalacturonide mixture at different noncytotoxic concentrations in the culture medium. A positive control was implemented in parallel (manganese chloride (0.5 mM)) to validate the experiment. After incubation, the cells were observed with a phase-contrast microscope to verify that the test had taken place correctly. [0066]
  • The characteristic spread of the keratinocytes on laminin [0067] 5 (Rousselle P. and Aumilley M., J. Cell. Biol., 1994, 125(1): 205-214) was taken into account. After rinsing, the remaining cells, adherent to the substrate, were fixed with a 1% glutaraldehyde solution in PBS for 15 minutes. After elimination of the fixative, the cells were stained with a crystal violet solution diluted to 1% in distilled water for 30 minutes. After intensive rinsing with water, the cells were permeabilized with a 0.02% triton solution for 15 minutes to solubilize the crystal violet.
  • An absorbance reading was performed at 570 nm using an ELISA plate reader. Each experimental point was performed in three samples. The blank value represents the mean of the absorbance of 3 control wells (BSA). This value was subtracted from each of the optical density values obtained for the experimental points. We then calculated the means of the three absorbance values for each of the triplicates. [0068]
  • 2) Results [0069]
  • a) Study of the Adhesion of Normal Human Keratinocytes on Laminin V [0070]
  • Manganese chloride (0.5 mM) was used as a positive control for the adhesion of the cells to the substrate. The adherence result obtained with the cells without active ingredient and without positive control was set arbitrarily at 100%. The active ingredient identified here constitutes the reference solution of oligosaccharides type oligo G04 (not lyophilized). [0071]
  • The results obtained are presented in Table 2 below. [0072]
    TABLE 2
    Laminin 5 Laminin 5
    3 μg/ml % SD 1.5 μg/ml % SD
    Cells alone 100 Cells alone 100
    MnCl2 97 6.4 MnCl2 109 5.1
    Solvent 101 0.96 Solvent 107 7.9
    Active 5% 103 0.16 Active 5% 119 1.4
      1% 116 14   1% 100 7.5
    0.01% 105 7.2 0.01% 105 7.5
  • The mixture induced an augmentation of 116% on laminin V at the concentration of 1%. [0073]
  • b) Study of the Adhesion of Normal Human Keratinocytes on Collagen IV [0074]
  • Manganese chloride (0.5 mM) was used as positive control for the adhesion of the cells to the substrate. The adherence results obtained with the cells without active ingredient and without positive control was set arbitrarily at 100%. [0075]
  • The results obtained are presented in Table 3 below. [0076]
    TABLE 3
    Collagen IV Collagen IV
    20 μg/ml % SD 10 μg/ml % SD
    Cells alone 100 Cells alone 100
    MnCl2 357 29 MnCl2 280 10
    Solvent 105 2.3 Solvent 90 3
    Active 5% 84 4.7 Active 5% 66 6
      1% 126 17   1% 90 15
    0.01% 101 5.9 0.01% 80 2.5
  • The mixture induced an augmentation of 126% on collagen IV at the concentration of 1%. [0077]
  • c) Study of the Morphology of Normal Human Keratinocytes after Adhesion on Laminin V or Collagen IV [0078]
  • Visualization of the spread and form of the adhered cells was performed by a demonstration of the cytoskeleton of actin by performing immunolabeling with phalloidin coupled to FITC. [0079]
  • Adhesion to Laminin V [0080]
  • FIGS. 1A and 1B show that, in the presence of the active ingredient used at 0.01% (FIG. 1B), the number of cells having adhered to laminin V was greater than in the control (FIG. 1A). These cells are more spread apart and the representative actin network of the cellular cytoskeleton is much better organized. These morphological changes due to the presence of the active ingredient (compared to the control) indicate that this ingredient truly promotes the recruitment and activation of the integrin α6β4. [0081]
  • Adhesion to Collagen IV [0082]
  • In the absence (FIG. 2A) or in the presence of the active ingredient (FIG. 2B), the cells adhere to collagen IV. However, it can be seen that in the presence of the active ingredient (FIG. 2B), the cells are larger, with a rather rounded shape with a very good cortical organization of the actin. In this case, the cells are joined, pressed against each other, indicating that the active ingredient stimulates cell-cell contacts and intercellular cohesion. [0083]
  • In conclusion, augmentation of the adherence of cells to laminin V in the presence of the active ingredient appears to come about via an augmentation of the expression of α6β4. The morphology and the spread of the cells on collagen IV in the presence of the active ingredient indicates that there is produced a recruitment of integrins α2β1 (specific to collagen IV) and that there also exists an enhanced cohesion among the keratinocytes. [0084]
  • III. Incorporation in a Cosmetic Formulation [0085]
  • In dry equivalents, the oligogalacturonides can be incorporated at the rate of about 0.1 to about 5%, preferably at the rate of about 0.5%. [0086]
  • 1) Example of Composition in Emulsion Form [0087]
    Water QSP
    Oligogalacturonides dp 1 to 5 (dry matter) 0.01 to 5%
    Mixture of preservatives  1.5%
    Propylene glycol 5.00%
    Xanthan gum 0.30%
    Acrylic/acrylate copolymer 0.50%
    Stearic acid 100 OE** 3.00%
    Sorbitan stearate 2.00%
    Sorbitan laurate 20 OE 3.00%
    Cetyl stearic alcohol 1.50%
    Bee's wax 1.00%
    Wheat germ oil 5.00%
    Dimethicone 2.00%
    Cyclomethicone 5.00%
    Polyacrylamide gel 2.00%
    Perfume 0.10%
  • 2) Example of Composition in Cream Form [0088]
    Water QSP
    Oligogalacturonides dp 1 to 5 (dry matter) 0.001% to 0.1%
    Xanthan gum 0.30%
    Sequestration agent (e.g., EDTA) 0.05%
    Preservatives 1.50%
    Acid C18 2.50%
    Acid C16 2.50%
    Trilaurin 1.00%
    Shea butter 3.00%
    Tocopherol acetate 0.05%
    β-bisabolol 0.05%
    Vegetable oil (wheat germ) 5.00%
    Dimethicone 3.00%
    Polyacrylic acid 0.30%
    TEA (triethanolamine) 1.50%
    Perfume 0.10%
  • 3) Example of Composition in Lotion Form [0089]
    Water QSP
    Oligogalacturonides dp 1 to 5 (dry matter) 0.001 to 0.1% 
    Sequestration agent 0.05%
    Propylene glycol 2.00%
    Mixture of preservatives  1.5%
    Alcohol  5 to 50%
    Oleic alcohol 20 OE 1.00%
    Perfume 0.05%

Claims (21)

1. A dermatological composition comprising:
a therapeutically effective amount of an agent stimulating adherence of basal keratinocytes to laminin V and/or collagen IV that reduces communication disturbances between a subject's dermis and epidermis and reduces diminishment in interkeratinocyte cohesion within the epidermis.
2. The composition according to claim 1, wherein the agent comprises oligogalacturonides having a degree of polymerization between about 1 and about 5.
3. The composition according to claim 1, wherein the agent comprises oligogalacturonides obtained by enzymatic hydrolysis of a pectin, the hydrolysis being performed by an enzyme cocktail comprising pectinases having polygalacturonase, methyl esterase and polygalacturonase lyase activities.
4. The composition according to claim 1, wherein the agent enhances availability of α6β4 receptors for laminin V and α2β1 receptors for collagen IV.
5. The composition according to claim 1, wherein the agent is at least partially methylated or esterified.
6. The composition according to claim 1, wherein the agent comprises about 0.01% to about 5% by weight of the composition.
7. The composition according to claim 1, further comprising at least one plant extract as another active component.
8. The composition according to claim 7, wherein the plant extract is selected from the group consisting of yam and beta carotene.
9. A method of preparing oligogalacturonides comprising:
hydrolysis of a pectin solution at a concentration of about 0.1 to about 10% at an acidic pH, by addition to the pectin solution of an enzyme solution of about 10 to about 1000 polygalacturonase units to obtain in a final solution of about 1 to about 10 pectinase units;
stopping the hydrolysis;
separating resulting high-molecular-weight polymers from the final solution; and
recovering the oligogalacturonides.
10. The method according to claim 9, wherein the hydrolysis of the pectin solution is performed with an enzyme solution comprising pectinases comprising polygalacturonase, methyl esterase and polygalacturonase lyase activities.
11. The method according to claim 9, wherein the hydrolysis is performed at a pH of about 4.5, at about 50° C. for about 2 hours then stepped by heating at about 70° C. for about 1 hour or at about 100° C. for about 5 minutes.
12. The method according to claim 11, wherein, after cooling, high-molecular-weight polymers are precipitated by addition of HCl 1N, then eliminated by centrifugation or by filtration, and the pH of the supernatant is readjusted to a value between about 6 and about 8.
13. A method of preventing aging of skin comprising applying a therapeutically effective amount of the composition comprising an agent stimulating adherence of basal keratinocytes to laminin V and/or collagen IV that reduces communication disturbances between a subject's dermis and epidermis and reduces diminishment in interkeratinocyte cohesion within the epidermis to the skin.
14. The composition according to claim 13, wherein the agent comprises oligogalacturonides having a degree of polymerization between about 1 and about 5.
15. The composition according to claim 13, wherein the agent comprises oligogalacturonides obtained by enzymatic hydrolysis of a pectin, the hydrolysis being performed by an enzyme cocktail comprising pectinases having polygalacturonase, methyl esterase and polygalacturonase lyase activities.
16. The composition according to claim 13, wherein the agent enhances availability of α6β4 receptors for laminin V and α2β1 receptors for collagen IV.
17. The composition according to claim 13, wherein the agent is at least partially methylated or esterified.
18. The composition according to claim 13, wherein the agent comprises about 0.01% to about 5% by weight of the composition.
19. The composition according to claim 13, further comprising at least one plant extract as another active component.
20. The composition according to claim 19, wherein the plant extract is selected from the group consisting of yam and beta carotene.
21. A method of reducing decreases in interkeratinocyte cohesion is skin comprising an agent stimulating adherence of basal keratinocytes to laminin V and/or collagen IV that reduces communication disturbances between a subject's dermis and epidermis and reduces diminishment in interkeratinocyte cohesion within the epidermis to the skin.
US10/839,420 2001-11-08 2004-05-05 Oligosaccharides in cosmetic or dermatological compositions for stimulating adhesion of keratinocytes to major proteins of the dermoepidermal junction and restoration of epidermal cohesion Abandoned US20040224892A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/894,945 US20070293433A1 (en) 2001-11-08 2007-08-22 Methods of treating aging of skin with oligosaccharides in cosmetic or dermatological compositions that stimulate adhesion of keratinocytes to major proteins of the dermoepidermal junction and restore epidermal cohesion

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0114463A FR2831819B1 (en) 2001-11-08 2001-11-08 USE OF OLIGOSACCHARIDES IN COSMETIC OR DERMATOLOGICAL COMPOSITIONS TO STIMULATE THE ADHESION OF KERATINOCYTES ON THE MAJOR PROTEINS OF THE DERMO-EPIDERMAL JUNCTION
FRFR01/14463 2001-11-08
PCT/FR2002/003844 WO2003039509A1 (en) 2001-11-08 2002-11-08 Use of oligosaccharides in cosmetic or dermatological compositions for stimulating adherence of keratinocytes on the dermoepidermal junction major proteins and restoring epidermal cohesion

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/003844 Continuation WO2003039509A1 (en) 2001-11-08 2002-11-08 Use of oligosaccharides in cosmetic or dermatological compositions for stimulating adherence of keratinocytes on the dermoepidermal junction major proteins and restoring epidermal cohesion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/894,945 Division US20070293433A1 (en) 2001-11-08 2007-08-22 Methods of treating aging of skin with oligosaccharides in cosmetic or dermatological compositions that stimulate adhesion of keratinocytes to major proteins of the dermoepidermal junction and restore epidermal cohesion

Publications (1)

Publication Number Publication Date
US20040224892A1 true US20040224892A1 (en) 2004-11-11

Family

ID=8869192

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/839,420 Abandoned US20040224892A1 (en) 2001-11-08 2004-05-05 Oligosaccharides in cosmetic or dermatological compositions for stimulating adhesion of keratinocytes to major proteins of the dermoepidermal junction and restoration of epidermal cohesion
US11/894,945 Abandoned US20070293433A1 (en) 2001-11-08 2007-08-22 Methods of treating aging of skin with oligosaccharides in cosmetic or dermatological compositions that stimulate adhesion of keratinocytes to major proteins of the dermoepidermal junction and restore epidermal cohesion

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/894,945 Abandoned US20070293433A1 (en) 2001-11-08 2007-08-22 Methods of treating aging of skin with oligosaccharides in cosmetic or dermatological compositions that stimulate adhesion of keratinocytes to major proteins of the dermoepidermal junction and restore epidermal cohesion

Country Status (4)

Country Link
US (2) US20040224892A1 (en)
DE (1) DE10297369T5 (en)
FR (1) FR2831819B1 (en)
WO (1) WO2003039509A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090075934A1 (en) * 2007-06-28 2009-03-19 Isabelle Bonnet Use of sulfated oligosaccharides as slimming cosmetic ingredients
JP2013529091A (en) * 2010-06-09 2013-07-18 シャネル パフュームズ ビューテ MicroRNA inhibitors for use in preventing and / or reducing skin aging and / or moisturizing skin
US8604001B2 (en) 2007-06-28 2013-12-10 Basf Beauty Care Solutions France S.A.S. Use of sulfated oligosaccharides as slimming cosmetic ingredients

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2852242B1 (en) * 2003-03-13 2007-09-14 USE OF OLIGOGALACTURONIDES IN COSMETICS OR FOR THE PREPARATION OF A DERMATOLOGICAL OR PHARMACEUTICAL COMPOSITION
FR2854573B1 (en) * 2003-05-06 2006-08-04 Rocher Yves Biolog Vegetale USE OF OLIGOSACCHARIDES IN COSMETIC OR DERMATOLOGICAL COMPOSITIONS FOR STIMULATING THE DIFFERENTIATION OF EPIDERMIC CELLS
MX2008013788A (en) * 2008-10-16 2010-04-16 Miguel Angel Martinez Tellez Method for controlling the table grape colouring, from oligogalacturonides.
FR3004936B1 (en) 2013-04-24 2016-02-05 Univ Reims Champagne Ardenne PROCESS FOR OBTAINING A MIXTURE OF NEUTRAL OLIGOSACCHARIDES EXTRACTED FROM FLAXSEED
FR3012334A1 (en) * 2013-10-29 2015-05-01 World Cosmetics ANTI AGE COSMETIC COMPOSITION

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105783A (en) * 1975-07-23 1978-08-08 Yu Ruey J Therapeutic treatment of dry skin
US5124313A (en) * 1989-06-02 1992-06-23 Schaeffer Hans A Methods of improved skin care and the treatment of dermatological conditions
US5561155A (en) * 1986-12-23 1996-10-01 Tristrata Technology, Inc. Method of treating wrinkles using galacturonic acid or galacturonolactone
US5683991A (en) * 1993-09-10 1997-11-04 Laevosan-Gesellschaft Blocking the attachment of germs to human cells
US5958474A (en) * 1996-08-21 1999-09-28 Nestec S.A. Process for preparing food flavor precursors
US6110478A (en) * 1996-06-12 2000-08-29 Laboratoire Oenobiol Composition having tanning and photoprotective activity, and its cosmetic applications

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0948732A (en) * 1995-08-04 1997-02-18 Pola Chem Ind Inc Activated oxygen scavenging agent and composition containing the same
JP3668538B2 (en) * 1995-08-30 2005-07-06 ポーラ化成工業株式会社 Active oxygen scavenger and composition containing the same
DE10006989A1 (en) * 2000-02-16 2001-08-23 Nutricia Nv Pharmaceutical or dietetic preparation for preventing cellular adhesion of pathogens, e.g. in treatment of infections, comprising carbohydrate having double bond-containing terminal uronic acid unit
DE10019076A1 (en) * 2000-04-06 2001-10-18 Lang Christine Use of polygalacturonides as food additives
FR2854573B1 (en) * 2003-05-06 2006-08-04 Rocher Yves Biolog Vegetale USE OF OLIGOSACCHARIDES IN COSMETIC OR DERMATOLOGICAL COMPOSITIONS FOR STIMULATING THE DIFFERENTIATION OF EPIDERMIC CELLS

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105783A (en) * 1975-07-23 1978-08-08 Yu Ruey J Therapeutic treatment of dry skin
US5561155A (en) * 1986-12-23 1996-10-01 Tristrata Technology, Inc. Method of treating wrinkles using galacturonic acid or galacturonolactone
US5124313A (en) * 1989-06-02 1992-06-23 Schaeffer Hans A Methods of improved skin care and the treatment of dermatological conditions
US5683991A (en) * 1993-09-10 1997-11-04 Laevosan-Gesellschaft Blocking the attachment of germs to human cells
US6110478A (en) * 1996-06-12 2000-08-29 Laboratoire Oenobiol Composition having tanning and photoprotective activity, and its cosmetic applications
US5958474A (en) * 1996-08-21 1999-09-28 Nestec S.A. Process for preparing food flavor precursors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090075934A1 (en) * 2007-06-28 2009-03-19 Isabelle Bonnet Use of sulfated oligosaccharides as slimming cosmetic ingredients
US8153611B2 (en) 2007-06-28 2012-04-10 Basf Beauty Care Solutions France S.A.S. Use of sulfated oligosaccharides as slimming cosmetic ingredients
US8604001B2 (en) 2007-06-28 2013-12-10 Basf Beauty Care Solutions France S.A.S. Use of sulfated oligosaccharides as slimming cosmetic ingredients
JP2013529091A (en) * 2010-06-09 2013-07-18 シャネル パフュームズ ビューテ MicroRNA inhibitors for use in preventing and / or reducing skin aging and / or moisturizing skin

Also Published As

Publication number Publication date
FR2831819B1 (en) 2004-09-03
DE10297369T5 (en) 2004-10-28
FR2831819A1 (en) 2003-05-09
WO2003039509A1 (en) 2003-05-15
US20070293433A1 (en) 2007-12-20

Similar Documents

Publication Publication Date Title
US20070293433A1 (en) Methods of treating aging of skin with oligosaccharides in cosmetic or dermatological compositions that stimulate adhesion of keratinocytes to major proteins of the dermoepidermal junction and restore epidermal cohesion
KR102268324B1 (en) A topical composition comprising small RNA lichen extract and cosmetic care method for reducing skin signs of aging
KR101323487B1 (en) Antiwrinkle agent
CN109152724B (en) Synergistic extract of palmaria palmiformis and jasmine, composition containing synergistic extract and application of synergistic extract
US6531132B1 (en) Process for the extraction of an active principle from yeast for the treatment of wrinkles and cosmetic compositions thereof
EP0668072A1 (en) Cosmetic composition containing a plant extracellular matrix extract
KR20210107724A (en) rosewood extract
KR102139472B1 (en) Anti-aging composition comprising functional peptides and fermented products
CN108703909B (en) Composition with anti-wrinkle and anti-aging effects and application of composition in cosmetics
JPH09241146A (en) Skin external agent
US6004568A (en) Cosmetic or pharmaceutical, particularly dermatological, composition containing a Bertholletia extract
US8293287B2 (en) Use of a Brassocattleya marcella Koss orchid extract as an active agent to prevent or delay the appearance of signs of cutaneous aging
US20070042064A1 (en) Extracts of durian fruit for use in skin care compositions
KR20210144725A (en) Anti-aging, antioxidant, anti-inflammatory and whitening agents, and cosmetics
KR101749657B1 (en) Cosmetic Composition Comprising Fermented product of Dendropanax morbifera Sap as Active Ingredient
JPH06336422A (en) External agent for skin
CN108785136B (en) Application of cedar essential oil
CN108992360A (en) It is a kind of add natural plant extracts skin care compositions and facial mask preparation method
US20070065386A1 (en) Use of oligosaccharides in cosmetic, food or dermatological compositions for stimulating the differentiation of epidermal cell
FR3111543A1 (en) NEW USES OF A ROSEWOOD EXTRACT
KR101957435B1 (en) Method for preparing extract of fermented silkworm cocoon for improving antiwrinkle and a cosmetic composition containing the fermented extract of silkworm cocoon as an active ingredients
KR20150031365A (en) Cosmetic Composition for Improving Skin Wrinkle Comprising the Fulvic acid
KR101825178B1 (en) Cosmetic composition comprising extract of dendropanax morbifera and d-asparatic acid with reinforced wrinkle elimanatin and whitening effect
FR3018448A1 (en) ACTIVE PRINCIPLE OBTAINED FROM ALGAE HYPNEA MUSCIFORMIS AND COSMETIC USES
KR20140072419A (en) Anti-Wrinkle Composition

Legal Events

Date Code Title Description
AS Assignment

Owner name: LABORATOIRES DE BIOLOGIE VEGETALE YVES ROCHER, FRA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LUBRANO, CHRISTIAN;FLAVET, LAURENCE;SAINTIGNY GAELLE;AND OTHERS;REEL/FRAME:015567/0880

Effective date: 20040608

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION